Lineage Cell Therapeutics (LCTX) Set to Post Earnings on Thursday

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) is projected to release its Q3 2026 results after the market closes on Thursday, November 5th. Analysts expect the company to announce earnings of ($0.02) per share and revenue of $2.32 million for the quarter. Interested persons may visit the company’s upcoming Q3 2026 earnings summary page for the latest details on the call scheduled for Thursday, November 5, 2026 at 4:30 PM ET.

Lineage Cell Therapeutics (NYSEAMERICAN:LCTX) last posted its quarterly earnings results on Thursday, August 6th. The company reported ($0.03) earnings per share (EPS) for the quarter, hitting the consensus estimate of ($0.03). The firm had revenue of $1.07 million during the quarter, compared to analysts’ expectations of $1.84 million. Lineage Cell Therapeutics had a negative net margin of 246.58% and a negative return on equity of 73.06%. On average, analysts expect Lineage Cell Therapeutics to post ($0.07) EPS for the current fiscal year and ($0.04) EPS for the next fiscal year.

Lineage Cell Therapeutics Stock Up 1.0%

Shares of NYSEAMERICAN:LCTX opened at $1.04 on Thursday. The company has a market cap of $263.03 million, a P/E ratio of -5.47 and a beta of 1.60. Lineage Cell Therapeutics has a 52 week low of $0.88 and a 52 week high of $2.09. The company has a 50-day moving average price of $1.02 and a 200 day moving average price of $1.34.

Analyst Upgrades and Downgrades

Separately, HC Wainwright reiterated a “buy” rating on shares of Lineage Cell Therapeutics in a research report on Tuesday, July 14th. Four investment analysts have rated the stock with a Buy rating. According to MarketBeat.com, Lineage Cell Therapeutics currently has a consensus rating of “Buy” and an average price target of $6.25.

Lineage Cell Therapeutics Company Profile

Lineage Cell Therapeutics, Inc is a biotechnology company focused on developing allogeneic cell therapies for unmet medical needs. The company uses its proprietary cell differentiation and manufacturing technologies to create specialized human cells intended to replace, repair or support damaged tissues.

Lineage’s lead program, OpRegen, is an investigational retinal pigment epithelium cell replacement therapy being developed for geographic atrophy, an advanced form of dry age-related macular degeneration.